Markets
XPH

Will a Clinton Presidency Spell Doom for Pharma ETFs?

Ongoing drug pricing controversy continues to weigh on the industry but there are several reasons to take a look at the beaten down ETFs.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

SPDR-SP PHARMA (XPH): ETF Research Reports

VANECK-PHARMA (PPH): ETF Research Reports

PWRSH-DYN PHARM (PJP): ETF Research Reports

ISHARS-US PHARM (IHE): ETF Research Reports

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

XPH PJP PPH IHE

Other Topics

Stocks